BioSpace News Archive

Deals

Why Boston-Bound Alexion Could be a Compelling M&A for Larger Drugmakers

With 2018 expected to be a big year for mergers and acquisitions in the biopharma industry, analysts and investors are considering who the top targets might be.

January 30, 2018
·
3 min read
·
Mark Terry
Biotech Bay

BridgeBio Launches QED Therapeutics With $65M and an Abandoned Novartis Cancer Program

BridgeBio stepped in to take over the drug and also launch a subsidiary, QED Therapeutics, to drive the development of infigratinib.

January 30, 2018
·
2 min read
·
Alex Keown
Biotech Bay

3 Overlooked Biopharmas Insiders are Snapping Up

A look at three intriguing biotech stocks that are seeing big insider buying from top-ranked insiders right now.

January 30, 2018
·
1 min read
Business

One-Year Old Dracen Pharma Raises $40.5M, Hunts for Office and Lab Space With Plans to Hire

The startup is working to develop pharmaceutical technology born out of Johns Hopkins University.

January 30, 2018
·
2 min read
·
Mark Terry
Pharm Country

New Report: J&J Tops Employment Branding

The companies were evaluated extensively on Career Pages, Job Boards, Employee Reviews & Candidate Engagement, Accolades, Recruitment Marketing, and Social Responsibility.

January 30, 2018
·
5 min read
·
Mark Terry
Business

Data Integrity, Business and Process Efficiencies Take Center Stage as CRF Health Appoints New Vice President of Quality Assurance

Haag’s role at CRF Health will be to oversee Quality across the organization.

January 30, 2018
·
2 min read
Drug Development

Pfizer Confirms Neuroscience Cuts, Shelves Another 4 Early-Stage Projects

During its financial report this morning, Pfizer released an update of its pipeline which includes the discontinued projects.

January 30, 2018
·
2 min read
·
Alex Keown
Policy

Unknown Group of Traders Earned $4.9M Before Sanofi-Bioverativ Deal

The SEC filed a suit against “one or more unknown traders” while it seeks to identify the perpetrators.

January 30, 2018
·
3 min read
·
Mark Terry
Business

Shire Snaps Up Rights to a Preclinical Autoimmune Candidate for Undisclosed Sum

Rare disease giant Shire plunked down an undisclosed sum to get its hands on a preclinical autoimmune drug candidate being developed by AB Biosciences.

January 30, 2018
·
2 min read
·
Alex Keown
Business

BioDuro Announces Cooperation Agreement With Porton Pharma Solutions

Under this agreement, BioDuro will promote and market Porton’s extensive and proven capabilities for pilot and large-scale GMP production of custom APIs and drug intermediates.

January 30, 2018
·
3 min read